The Dark Side of Genomics

By BIO-IT World

April 15, 2003 | Identifying genes is one of the more glamorous aspects of genomics, but it's difficult picking out the 1 percent to 2 percent of coding sequences amid all the nonsense and junk DNA.

Most genes undergo alternative splicing, producing two or more different proteins. Then, there are pseudogenes — genes that look functional but aren't. Some of these are "dead genes," according to University of California at Santa Cruz bioinformatician David Haussler. "They once had a function," he says, "but they have accumulated enough mutations to slowly decay and become worthless." Distinguishing functional genes from pseudogenes is not trivial.

Thanks in part to the mouse genome, completed last year (see Paper View, Feb. 2003 Bio·IT World), the emerging consensus is that the total number of human genes is less than the initial 30,000 estimate. But uncertainty remains, and Haussler concedes that "computational prediction of genes is simply very hard." New programs such as TwinScan from Washington University in St. Louis, and Genomix's EXP6, are assisting efforts to not only identify novel genes but also confirm the existence of "dark genes" — those predicted by computer programs but unverified by other techniques.

AnVil and Applied Biosystems (ABI) collaborated to shed light on the "dark" genome using PCR (polymerase chain reaction) methods with TaqMan, microarrays, and AnVil's advanced analytics, to study about 10,000 putative genes. AnVil designed the analytical program that "determines whether the lab data are hard evidence that these are genes," AnVil's John McCarthy says. Once "found again," those genes will help finalize the actual number of genes. ABI reports that 2,400 to 2,500 genes were confirmed after screening 9,500 predicted ones. Aside from the inherent scientific interest, "The assays for those genes will make a nice addition to our offering," ABI's Raymond Samaha says.

Ultimately, identifying all genes will be a walk in the park compared to what lies ahead. Eric Green of the National Human Genome Research Center says: "We will find all the genes. But we aren't even in diapers yet in terms of finding all the other stuff — the functionally important sequences and the regulatory elements."

—Malorye Branca

Back to Beyond the Blueprint 




White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.